ProQR Therapeutics N.V. (PRQR) stock
PRQRNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.15−0.03 (-2.54%)
Close on Nov 17, 2026Market cap $121.17MP/E –Yield –
ProQR Therapeutics profit margin
Profit margin (net margin) is net income as a percentage of revenue.
ProQR Therapeutics's profit margin for the twelve months ending Jun 30, 2026 was -228.9%. For fiscal 2025 it was -265.2%, against -146.9% the year before. The highest annual figure on record is -146.9% in fiscal 2024.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -265.2% | −118.4 |
| FY2024 | Dec 31, 2024 | -146.9% | +284.8 |
| FY2023 | Dec 31, 2023 | -431.7% | +1360.9 |
| FY2022 | Dec 31, 2022 | -1792.5% | +2757.3 |
| FY2021 | Dec 31, 2021 | -4549.8% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -99.6% | +219.4 |
| Q1 FY2026 | Mar 31, 2026 | -658.3% | −435.3 |
| Q4 FY2025 | Dec 31, 2025 | -190.3% | +25.8 |
| Q3 FY2025 | Sep 30, 2025 | -381.9% | −170.9 |
| Q2 FY2025 | Jun 30, 2025 | -319.1% | −276.4 |
| Q1 FY2025 | Mar 31, 2025 | -223.0% | −50.9 |
| Q4 FY2024 | Dec 31, 2024 | -216.0% | −49.1 |
| Q3 FY2024 | Sep 30, 2024 | -211.0% | +205.8 |
| Q2 FY2024 | Jun 30, 2024 | -42.7% | +620.6 |
| Q1 FY2024 | Mar 31, 2024 | -172.1% | +1191.7 |
| Q4 FY2023 | Dec 31, 2023 | -167.0% | +1679.8 |
| Q3 FY2023 | Sep 30, 2023 | -416.8% | +2447.8 |
| Q2 FY2023 | Jun 30, 2023 | -663.3% | +809.8 |
| Q1 FY2023 | Mar 31, 2023 | -1363.8% | −115.2 |
| Q4 FY2022 | Dec 31, 2022 | -1846.8% | +5777.0 |
| Q3 FY2022 | Sep 30, 2022 | -2864.6% | −1139.0 |
| Q2 FY2022 | Jun 30, 2022 | -1473.1% | +5006.7 |
| Q1 FY2022 | Mar 31, 2022 | -1248.6% | – |
| Q4 FY2021 | Dec 31, 2021 | -7623.8% | – |
| Q3 FY2021 | Sep 30, 2021 | -1725.6% | – |
| Q2 FY2021 | Jun 30, 2021 | -6479.8% | – |
See a number that looks wrong?